Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia

Watanabe, Kenya; Miura, Itaru; Kanno-Nozaki, Keiko; Horikoshi, Sho; Mashiko, Hirobumi; Niwa, Shin‐Ichi

doi:10.1016/j.psychres.2015.09.030

Cited by 11 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with a previous study suggesting that plasma HVA and MHPG levels are associated with psychotic or excitement symptoms in patients with schizophrenia 7. Moreover, a previous report8 has demonstrated that plasma levels of HVA and MHPG were increased in systemic lupus erythematosus patients with psychiatric symptoms, which is consistent with our findings.…”

Section: Discussionsupporting

confidence: 94%

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Horikoshi

Miura²,

Kunii³

et al. 2017

NDT

Self Cite

View full text Add to dashboard Cite

Hashimoto encephalopathy (HE) is believed to be an immune-mediated disorder associated with Hashimoto’s thyroiditis. It was suggested that neuropsychiatric symptoms, the presence of antithyroid antibody, and good response to steroids were important for the diagnosis of HE. It has been reported that homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), which are monoamine metabolites of dopamine and noradrenaline, respectively, are the possible biomarkers of neuropsychiatric diseases. We report a case of Hashimoto encephalopathy, in which we longitudinally measured the plasma levels of monoamine metabolites. A 52-year-old woman developed acute psychosis, and was admitted to the psychiatric ward of our hospital due to psychotic state, 6 days after a traffic accident. An extensive evaluation showed no remarkable findings, except an increase in antithyroglobulin antibodies. Plasma levels of HVA and MHPG were extremely high at 66.5 and 41.8 ng/mL, respectively. On day 16, 50 mg/day oral prednisolone was administered, which improved her psychotic symptoms. Plasma levels of HVA and MHPG decreased to 7.2 and 9.9 ng/mL, respectively, on day 19. After the temporary worsening of psychosis and increase in plasma levels of HVA and MHPG, the dosage of prednisolone was tapered and low-dose risperidone was started. Her psychiatric symptoms gradually improved and plasma monoamine metabolite levels decreased again (HVA: 17.9 ng/mL; MHPG: 7.7 ng/mL). Although autoimmune mechanism has been suggested to be involved in HE, neural mechanism and pathogenesis of HE remain unknown. Our findings suggest that monoaminergic neural activity might be associated with psychotic symptoms in patients with HE and plasma levels of monoamine metabolites might be useful as state markers.

show abstract

Section: Discussionsupporting

confidence: 94%

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Horikoshi

Miura²,

Kunii³

et al. 2017

NDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although our purpose here was not to compare urine vs plasma samplings, it must be noted that because of these increases of specificity and sensitivity, assays in the plasma have been described for 5HIAA, metanephrines and methoxytyramine, VMA and HVA (72, 73, 112, 113, 114, 115). It is possible that these plasma assays will supplant urine assays for tumour assessment.…”

Section: Resultsmentioning

confidence: 99%

Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations

Corcuff

Chardon

Ridah³

et al. 2017

Endocrine Connections

View full text Add to dashboard Cite

ContextBiogenic amines such as 5-hydroxy-indole acetic acid (5HIAA) the main metabolite of serotonin or metanephrines (catecholamines metabolites) are used as biomarkers of neuroendocrine tumours.ObjectiveTo re-evaluate the recommendations for urinary sampling (preservatives, diet, drugs, etc.) as many of the reported analytical interferences supporting these recommendations are related to obsolete assays.MethodsBibliographic analysis of old and modern assays concerning preservation, extraction, assay and interferences.Results5HIAA may degrade as soon as urine is excreted. Thus, acids as preservatives (hydrochloric or acetic acid) have to be immediately added. Care should be taken not to decrease the pH under 2. Urine preservative for metanephrine assays is not mandatory. Diets including serotonin-, tryptophan- and dopamine-rich foods have to be avoided depending on the biomarkers investigated (bananas, plantain, nuts, etc.). Tryptophan-rich over-the-counter formulas have to be prohibited when 5HIAA has to be assayed. Acetaminophen may interfere with electrochemical detection depending on high-pressure liquid chromatography (HPLC) parameters. No interference is known with mass spectrometric assays but with the one described for metanephrines determination. Some drugs interfere however with serotonin and catecholamines secretion and/or metabolism (monoamine oxidase inhibitors, serotonin or dopamine recapture inhibitors, etc.).ConclusionRevisited recommendations are provided for the diet, the drugs and the preservatives before HPLC coupled with electrochemical and mass spectrometry assays.

show abstract

“…Concentrations of plasma monoamine metabolites were analyzed with high-performance liquid chromatography with electrochemical detection. Plasma levels of HVA and MHPG were analyzed using the methods of Watanabe et al 19 The intra-assay coefficients of variation for plasma HVA and MHPG in our laboratory were 3.2% and 3.1%, respectively. The interassay coefficients of variation for plasma HVA and MHPG were 8.6% and 7.6%, respectively.…”

Section: Methodsmentioning

confidence: 99%

<em>COMT</em> Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

Kaneko

Miura

Kanno-Nozaki

et al. 2018

NDT

Self Cite

View full text Add to dashboard Cite

IntroductionThe COMT Val 108/158 Met polymorphism (rs4680) may affect treatment response to antipsychotics, as well as metabolism and dynamics of neurotransmitters during the treatment of schizophrenia. We investigated the effects of the COMT Val 108/158 Met polymorphism on treatment response to aripiprazole and plasma monoamine metabolite levels in patients with acute schizophrenia.Materials and methodsForty patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured Positive and Negative Syndrome Scale (PANSS) and plasma levels of homovanillic acid (HVA) and plasma MHPG (3-methoxy-4-hydroxyphenethyleneglycol) at baseline and endpoint. The COMT Val 108/158 Met polymorphism was genotyped with the polymerase chain reaction and restriction fragment length polymorphism.ResultsThere were significant genotype–time interactions on PANSS total and general psychopathology scores, with Met/Met genotype showing greater improvement. The response rate to aripiprazole did not differ between COMT Val 108/158 Met genotype groups. We found a significant time effect on plasma MHPG levels, but no time effect on plasma HVA levels or time–genotype interactions in the plasma levels of HVA and MHPG. Although the responder rate did not differ among the 3 genotype groups.ConclusionOur results suggest that individuals with the Met/Met genotype had greater improvement in PANSS score after the treatment with aripiprazole. On the other hand, the Val 108/158 Met polymorphism may not induce changes in plasma levels of monoamine metabolites during aripiprazole treatment. Because of the small sample size, further studies are needed to confirm and to extend our results.

show abstract

Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia

Cited by 11 publications

References 38 publications

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report

Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations

<em>COMT</em> Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

Contact Info

Product

Resources

About